Ujvira Injection (100mg), which contains Trastuzumab, is a targeted therapy primarily used in the treatment of certain types of breast cancer and gastric cancer that overexpress the HER2 protein. This monoclonal antibody works by binding to the HER2 receptor on cancer cells, inhibiting their growth and promoting cell death. Ujvira is typically administered intravenously and is often part of a comprehensive treatment plan that may include chemotherapy. The composition of Ujvira Injection includes Trastuzumab as the active ingredient, along with various excipients that facilitate its delivery and stability. This medication is crucial for patients with HER2-positive cancers, providing a more personalized approach to cancer treatment and improving overall outcomes.